Inventage Lab Secures Patent for Semaglutide Microparticles and Manufacturing Method Using IVL-DrugFluidic Platform
Inventage Lab, a company specializing in long-acting injectable microspheres and lipid nanoparticle (LNP) manufacturing platforms, announced on November 17 that it has secured a patent for semaglutide microparticles and its proprietary manufacturing method.
The newly registered patent is a foundational intellectual property for producing semaglutide microparticle formulations using the company's proprietary platform, IVL-DrugFluidic. According to Inventage Lab, this patent establishes a strong technological entry barrier as it can only be implemented through the unique capabilities of IVL-DrugFluidic. This exclusivity is expected to provide the company with long-term competitive advantages in the production of related products.
Inventage Lab's IVL-DrugFluidic platform enables the production of long-acting injectable formulations using high-quality polymer-based microparticles. The platform aims to minimize the side effects of active pharmaceutical ingredients (APIs) while achieving sustained drug release, offering a next-generation approach to drug delivery.
The company has filed 75 patents in South Korea and abroad, with 27 of them already granted. This latest patent adds to its growing intellectual property portfolio, solidifying its position as a leader in microparticle technology. Amid fierce competition for semaglutide-related patents, Inventage Lab has successfully differentiated itself by applying its proprietary platform, establishing a significant technological barrier for potential competitors.
The CEO of Inventage Lab commented, "This patent registration secures a key technological asset necessary for developing long-acting injectable formulations for obesity treatments. We will continue to enhance our platform to demonstrate competitiveness in the global obesity treatment market."
With this patent in place, Inventage Lab aims to strengthen its position in the market for long-acting injectable obesity treatments and reinforce its technological leadership in the development of next-generation drug delivery platforms.
